After a week’s break , Johnson & Johnson is now continuing their rolloutvaccine in Europe.
This is stated by the pharmaceutical company in a press release .
The decision comes after the European Medicines Agency (EMA) today concluded that: the vaccine is safe and effective and that the benefits ofthe vaccine outweighs the risks.
The EMA reported that there were some very rare cases of platelets with low platelet counts vaccinated – and that this should be stated invaccines .
Johnson & Johnson says they will now update the package leaflet in the vaccine with this information.